Currently approved SARS-CoV-2 vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa, meaning that they are highly effective ...
DOI: https://doi.org/10.1038/s41590-022-01405-w https://doi.org/10.1038/s41590-022-01405-w Thus, a prime and spike regimen induces a protective mucosal immune response and reduces the transmission of SARS-CoV-2.